Nymox Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-4.49	-8.84	-6.58	-12.54	-11.74	Upgrade
Depreciation & Amortization	0	0.17	0.25	0.23	0.26	Upgrade
Stock-Based Compensation	0.67	3.36	0.59	2.6	1.75	Upgrade
Other Operating Activities	-	0.44	0.03	0.02	0.01	Upgrade
Change in Accounts Receivable	-	-	-	-	-0	Upgrade
Change in Inventory	-	-	-	-	-0.01	Upgrade
Change in Accounts Payable	1.24	1.32	0.38	-0.17	-0.17	Upgrade
Change in Other Net Operating Assets	-0.02	-0.5	0.12	0.03	-0.13	Upgrade
Operating Cash Flow	-2.6	-4.06	-5.21	-9.82	-10.04	Upgrade
Capital Expenditures	-	-0	-	-0.01	-0.01	Upgrade
Investing Cash Flow	-	-0	-	-0.01	-0.01	Upgrade
Short-Term Debt Issued	2.67	1.75	-	-	-	Upgrade
Total Debt Issued	2.67	1.75	-	-	-	Upgrade
Long-Term Debt Repaid	-0.06	-0.17	-0.23	-0.24	-0.27	Upgrade
Net Debt Issued (Repaid)	2.61	1.58	-0.23	-0.24	-0.27	Upgrade
Issuance of Common Stock	-	1.15	4.27	6.95	8.69	Upgrade
Other Financing Activities	-	-	1.74	0.33	-	Upgrade
Financing Cash Flow	2.61	2.73	5.78	7.05	8.42	Upgrade
Net Cash Flow	0	-1.33	0.57	-2.78	-1.63	Upgrade
Free Cash Flow	-2.6	-4.06	-5.21	-9.83	-10.05	Upgrade
Free Cash Flow Margin	-	-	-	-	-201000.00%	Upgrade
Free Cash Flow Per Share	-0.03	-0.04	-0.06	-0.12	-0.14	Upgrade
Levered Free Cash Flow	-1.08	-1.12	-2.81	-5.15	-5.68	Upgrade
Unlevered Free Cash Flow	-0.94	-1.08	-2.79	-5.12	-5.65	Upgrade
Change in Working Capital	1.22	0.82	0.5	-0.14	-0.31	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.